Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Grünenthal On Hunt For Asia Partner As Pain Killer Hits Phase III Endpoints

Executive Summary

Grünenthal’s novel pain killer has succeeded in a Phase III trial in cancer pain and now the company wants to find a partner for Asian markets, to complement its deal last year with Depomed for North America.

You may also be interested in...



Deal Watch: AZ, Alchemab To Study Immune Response For Novel Cancer Targets

Also, deals involving AbCellera/Angios, AstraZeneca/Alchemab, Kowa/Esteve, OSE/Veloxis, Tris/Park, Core One/Akome and Vertex/Obsidian.

Antibe Speeds Hydrogen Sulfide-Releasing NSAID Development

Canada’s Antibe Therapeutics is accelerating the early-stage clinical development of new molecules that depend on the cytoprotective and signaling properties of minute amounts of hydrogen sulfide to have a potent anti-inflammatory and analgesic effect.

10 US Approval Decisions To Look Out For In Q3

This quarter has already seen a complete response letter for Iterum Therapeutics’ antibiotic sulopenem but a raft of other products are expecting approval decisions from the US Food and Drug Administration in the next three months. With the help of analysts at Biomedtracker, Scrip takes a look at 10 of the more interesting ones.

Topics

Related Companies

UsernamePublicRestriction

Register

SC097407

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel